Phase I/IB trial of eribulin and everolimus in patients with triple-negative metastatic breast cancer.

被引：1
|
作者：
Luu, Thehang H. [1 ]
Blanchard, Suzette [1 ]
Yim, John Hosei [1 ]
机构：
[1] City Hope Canc Ctr, Beckman Res Inst, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.tps2637
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2637
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II Trial of Brostallicin and Cisplatin in Patients with Metastatic Triple Negative Breast Cancer.
    Moreno-Aspitia, A.
    Rowland, K. M.
    Liu, H.
    Hillman, D. W.
    Stella, P. J.
    Perez, E. A.
    CANCER RESEARCH, 2011, 71
  • [22] A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers
    Roviello, Giandomenico
    Milani, Manuela
    Gobbi, Angela
    Cappelletti, Maria Rosa
    Zanotti, Laura
    Senti, Chiara
    Bottini, Alberto
    Strina, Carla
    Sigala, Sandra
    Generali, Daniele
    CLINICAL BREAST CANCER, 2016, 16 (03) : E57 - E59
  • [23] A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1).
    Tolaney, Sara M.
    Kalinsky, Kevin
    Kaklamani, Virginia G.
    D'Adamo, David R.
    Aktan, Gursel
    Tsai, Michaela L.
    O'Regan, Ruth
    Kaufman, Peter A.
    Wilks, Sharon
    Andreopoulou, Eleni
    Patt, Debra A.
    Yuan, Yuan
    Wang, Grace
    Xing, Dongyuan
    Kleynerman, Ella
    Karantza, Vassiliki
    Diab, Sami
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes
    Yonemori, Kan
    Shimomura, Akihiko
    Yasojima, Hiroyuki
    Masuda, Norikazu
    Aogi, Kenjiro
    Takahashi, Masato
    Naito, Yoichi
    Shimizu, Satoru
    Nakamura, Rikiya
    Hashimoto, Jun
    Yamamoto, Harukaze
    Hirakawa, Akihiro
    Michimae, Hirofumi
    Hamada, Akinobu
    Yoshida, Teruhiko
    Sukigara, Tamie
    Tamura, Kenji
    Fujiwara, Yasuhiro
    EUROPEAN JOURNAL OF CANCER, 2019, 109 : 84 - 91
  • [25] A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer.
    Mitri, Zahi Ibrahim
    Vuky, Jacqueline
    Kemmer, Kathleen A.
    Savin, Michael A.
    Parmar, Swapnil
    Kolodzie, Annette Kolodzie
    Johnson, Brett
    Williams-Belizaire, Rochelle
    Gray, Joe W.
    Mills, Gordon B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer.
    Wang, Jiayu
    Xu, Binghe
    Sun, Tao
    Ouyang, Quchang
    Han, Yiqun
    Li, Qing
    Zhang, Pin
    Ma, Fei
    Luo, Yang
    Fan, Ying
    Cai, Ruigang
    Li, Qiao
    Lan, Bo
    Mo, Hongnan
    Wang, Jiani
    Li, Yiqun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
    Zhang, Qingyuan
    Shao, Bin
    Tong, Zhongsheng
    Ouyang, Quchang
    Wang, Yuting
    Xu, Guoying
    Li, Shaorong
    Li, Huiping
    BMC MEDICINE, 2022, 20 (01)
  • [28] A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
    Qingyuan Zhang
    Bin Shao
    Zhongsheng Tong
    Quchang Ouyang
    Yuting Wang
    Guoying Xu
    Shaorong Li
    Huiping Li
    BMC Medicine, 20
  • [29] Patterns of mutation enrichment in metastatic triple-negative breast cancer.
    Saravia, Cesar H.
    Flores, Claudio J.
    Schwarz, Luis Jesus
    Bravo, Leny
    Zavaleta, Jenny
    Araujo, Jhajaira M.
    Neciosup, Silvia P.
    Pinto, Joseph A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer.
    O'Shaughnessy, Joyce
    Osborne, Cynthia
    Pippen, John E.
    Yoffe, Mark
    Patt, Debra
    Rocha, Christine
    Koo, Ingrid Chou
    Sherman, Barry M.
    Bradley, Charles
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (03): : 205 - 214
12345